Harnessing role of sesamol and its nanoformulations against neurodegenerative diseases
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Sesamol is a lignan of sesame seeds and a natural phenolic molecule that has emerged as a useful medical agent. Sesamol is a non-toxic phytoconstituent, which exerts certain valuable effects in the management of cancer, diabetes, cardiovascular diseases, neurodegenerative diseases (NDs), etc. Sesamol is known to depict its neuroprotective role by various mechanisms, such as metabolic regulators, action on oxidative stress, neuroinflammation, etc. However, its poor oral bioavailability, rapid excretion (as conjugates), and susceptibility to gastric irritation/toxicity (particularly in rats' forestomach) may restrict its effectiveness. To overcome the associated limitations, novel drug delivery system-based formulations of sesamol are emerging and being researched extensively. These can conjugate with sesamol and enhance the bioavailability and solubility of free sesamol, along with delivery at the target site. In this review, we have summarized various research works highlighting the role of sesamol on various NDs, including Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, and Parkinson's disease. Moreover, the formulation strategies and neuroprotective role of sesamol-based nano-formulations have also been discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 167(2023) vom: 11. Nov., Seite 115512 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Navneet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioavailability |
|---|
| Anmerkungen: |
Date Revised 17.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.biopha.2023.115512 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362226970 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362226970 | ||
| 003 | DE-627 | ||
| 005 | 20231226090811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.115512 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362226970 | ||
| 035 | |a (NLM)37725878 | ||
| 035 | |a (PII)S0753-3322(23)01310-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Navneet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Harnessing role of sesamol and its nanoformulations against neurodegenerative diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Sesamol is a lignan of sesame seeds and a natural phenolic molecule that has emerged as a useful medical agent. Sesamol is a non-toxic phytoconstituent, which exerts certain valuable effects in the management of cancer, diabetes, cardiovascular diseases, neurodegenerative diseases (NDs), etc. Sesamol is known to depict its neuroprotective role by various mechanisms, such as metabolic regulators, action on oxidative stress, neuroinflammation, etc. However, its poor oral bioavailability, rapid excretion (as conjugates), and susceptibility to gastric irritation/toxicity (particularly in rats' forestomach) may restrict its effectiveness. To overcome the associated limitations, novel drug delivery system-based formulations of sesamol are emerging and being researched extensively. These can conjugate with sesamol and enhance the bioavailability and solubility of free sesamol, along with delivery at the target site. In this review, we have summarized various research works highlighting the role of sesamol on various NDs, including Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, and Parkinson's disease. Moreover, the formulation strategies and neuroprotective role of sesamol-based nano-formulations have also been discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bioavailability | |
| 650 | 4 | |a Nanoformulations | |
| 650 | 4 | |a Neurodegenerative diseases | |
| 650 | 4 | |a Neuroprotective effects | |
| 650 | 4 | |a Sesamol | |
| 700 | 1 | |a Vishwas, Sukriti |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Amandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Harmanpreet |e verfasserin |4 aut | |
| 700 | 1 | |a Kakoty, Violina |e verfasserin |4 aut | |
| 700 | 1 | |a Khursheed, Rubiya |e verfasserin |4 aut | |
| 700 | 1 | |a Chaitanya, M V N L |e verfasserin |4 aut | |
| 700 | 1 | |a Babu, Molakpogu Ravindra |e verfasserin |4 aut | |
| 700 | 1 | |a Awasthi, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Corrie, Leander |e verfasserin |4 aut | |
| 700 | 1 | |a Harish, Vancha |e verfasserin |4 aut | |
| 700 | 1 | |a Yanadaiah, Palakurthi |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Sayed, Amany A |e verfasserin |4 aut | |
| 700 | 1 | |a El-Sayed, Amr |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Iftikhar |e verfasserin |4 aut | |
| 700 | 1 | |a Kensara, Osama A |e verfasserin |4 aut | |
| 700 | 1 | |a Ghaboura, Nehmat |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, Ali M |e verfasserin |4 aut | |
| 700 | 1 | |a Algahtani, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a El-Kott, Attalla F |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sachin Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Daim, Mohamed M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 167(2023) vom: 11. Nov., Seite 115512 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2023 |g day:11 |g month:11 |g pages:115512 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.115512 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2023 |b 11 |c 11 |h 115512 | ||